vs
AETHLON MEDICAL INC（AEMD）与MERIT MEDICAL SYSTEMS INC（MMSI）财务数据对比。点击上方公司名可切换其他公司
MERIT MEDICAL SYSTEMS INC的季度营收约是AETHLON MEDICAL INC的6569.5倍（$393.9M vs $60.0K）。MERIT MEDICAL SYSTEMS INC净利率更高（9.6% vs -2926.4%，领先2936.0%）。MERIT MEDICAL SYSTEMS INC自由现金流更多（$74.0M vs $-2.0M）
AETHLON MEDICAL INC是一家临床阶段医疗科技企业，专注开发针对性治疗类医疗器械，核心产品血液净化器可从血液中去除有害病毒、肿瘤外泌体及其他病原体，业务聚焦传染病和肿瘤治疗赛道，主要市场覆盖北美地区。
梅里特医疗系统公司是一家全球性医疗设备企业，设计、生产和销售适用于心脏病学、放射学、肿瘤学、内窥镜及重症监护领域的介入和诊断产品，为全球医院及医疗机构提供微创医疗解决方案，助力提升患者疗效和临床操作效率。
AEMD vs MMSI — 直观对比
营收规模更大
MMSI
是对方的6569.5倍
$60.0K
净利率更高
MMSI
高出2936.0%
-2926.4%
自由现金流更多
MMSI
多$76.1M
$-2.0M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $60.0K | $393.9M |
| 净利润 | $-1.8M | $38.0M |
| 毛利率 | — | 49.6% |
| 营业利润率 | -3026.4% | 13.8% |
| 净利率 | -2926.4% | 9.6% |
| 营收同比 | — | 10.9% |
| 净利润同比 | 49.4% | 36.0% |
| 每股收益（稀释后） | $-10.05 | $0.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEMDMMSI
| Q4 25 | — | $393.9M | ||
| Q3 25 | — | $384.2M | ||
| Q2 25 | — | $382.5M | ||
| Q1 25 | — | $355.4M | ||
| Q4 24 | $60.0K | $355.2M | ||
| Q3 24 | $95.1K | $339.8M | ||
| Q2 24 | — | $338.0M | ||
| Q1 24 | — | $323.5M |
净利润AEMDMMSI
| Q4 25 | — | $38.0M | ||
| Q3 25 | — | $27.8M | ||
| Q2 25 | — | $32.6M | ||
| Q1 25 | — | $30.1M | ||
| Q4 24 | $-1.8M | $27.9M | ||
| Q3 24 | $-2.8M | $28.4M | ||
| Q2 24 | — | $35.7M | ||
| Q1 24 | — | $28.2M |
毛利率AEMDMMSI
| Q4 25 | — | 49.6% | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | 48.7% | ||
| Q3 24 | — | 46.4% | ||
| Q2 24 | — | 47.7% | ||
| Q1 24 | — | 46.9% |
营业利润率AEMDMMSI
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 11.1% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 11.5% | ||
| Q4 24 | -3026.4% | 10.3% | ||
| Q3 24 | -3050.2% | 11.0% | ||
| Q2 24 | — | 13.6% | ||
| Q1 24 | — | 11.1% |
净利率AEMDMMSI
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | — | 8.5% | ||
| Q1 25 | — | 8.5% | ||
| Q4 24 | -2926.4% | 7.9% | ||
| Q3 24 | -2950.2% | 8.4% | ||
| Q2 24 | — | 10.6% | ||
| Q1 24 | — | 8.7% |
每股收益（稀释后）AEMDMMSI
| Q4 25 | — | $0.64 | ||
| Q3 25 | — | $0.46 | ||
| Q2 25 | — | $0.54 | ||
| Q1 25 | — | $0.49 | ||
| Q4 24 | $-10.05 | $0.46 | ||
| Q3 24 | $-16.11 | $0.48 | ||
| Q2 24 | — | $0.61 | ||
| Q1 24 | — | $0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.8M | $446.4M |
| 总债务越低越好 | — | $734.0M |
| 股东权益账面价值 | $4.3M | $1.6B |
| 总资产 | $6.5M | $2.7B |
| 负债/权益比越低杠杆越低 | — | 0.46× |
8季度趋势，按日历期对齐
现金及短期投资AEMDMMSI
| Q4 25 | — | $446.4M | ||
| Q3 25 | — | $392.5M | ||
| Q2 25 | — | $341.8M | ||
| Q1 25 | — | $395.5M | ||
| Q4 24 | $4.8M | $376.7M | ||
| Q3 24 | $6.9M | $523.1M | ||
| Q2 24 | — | $636.7M | ||
| Q1 24 | — | $581.9M |
总债务AEMDMMSI
| Q4 25 | — | $734.0M | ||
| Q3 25 | — | $732.9M | ||
| Q2 25 | — | $731.8M | ||
| Q1 25 | — | $730.7M | ||
| Q4 24 | — | $729.6M | ||
| Q3 24 | — | $750.5M | ||
| Q2 24 | — | $801.3M | ||
| Q1 24 | — | $800.1M |
股东权益AEMDMMSI
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $4.3M | $1.4B | ||
| Q3 24 | $6.0M | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.2B |
总资产AEMDMMSI
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $6.5M | $2.4B | ||
| Q3 24 | $8.8M | $2.4B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.3B |
负债/权益比AEMDMMSI
| Q4 25 | — | 0.46× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.62× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $98.5M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $74.0M |
| 自由现金流率自由现金流/营收 | -3357.0% | 18.8% |
| 资本支出强度资本支出/营收 | 3.7% | 6.2% |
| 现金转化率经营现金流/净利润 | — | 2.59× |
| 过去12个月自由现金流最近4个季度 | — | $215.7M |
8季度趋势，按日历期对齐
经营现金流AEMDMMSI
| Q4 25 | — | $98.5M | ||
| Q3 25 | — | $75.0M | ||
| Q2 25 | — | $83.3M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | $-2.0M | $68.7M | ||
| Q3 24 | $-2.2M | $47.3M | ||
| Q2 24 | — | $68.5M | ||
| Q1 24 | — | $36.2M |
自由现金流AEMDMMSI
| Q4 25 | — | $74.0M | ||
| Q3 25 | — | $52.5M | ||
| Q2 25 | — | $69.6M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | $-2.0M | $65.3M | ||
| Q3 24 | — | $38.0M | ||
| Q2 24 | — | $57.9M | ||
| Q1 24 | — | $24.5M |
自由现金流率AEMDMMSI
| Q4 25 | — | 18.8% | ||
| Q3 25 | — | 13.7% | ||
| Q2 25 | — | 18.2% | ||
| Q1 25 | — | 5.5% | ||
| Q4 24 | -3357.0% | 18.4% | ||
| Q3 24 | — | 11.2% | ||
| Q2 24 | — | 17.1% | ||
| Q1 24 | — | 7.6% |
资本支出强度AEMDMMSI
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 5.8% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 5.9% | ||
| Q4 24 | 3.7% | 1.0% | ||
| Q3 24 | 0.0% | 2.8% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 3.6% |
现金转化率AEMDMMSI
| Q4 25 | — | 2.59× | ||
| Q3 25 | — | 2.70× | ||
| Q2 25 | — | 2.56× | ||
| Q1 25 | — | 1.35× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.92× | ||
| Q1 24 | — | 1.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AEMD
暂无分部数据
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
